Patents by Inventor Max V. Rasmussen
Max V. Rasmussen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10865389Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.Type: GrantFiled: March 29, 2019Date of Patent: December 15, 2020Assignee: The Government of the United States of America, as represented by the Secretary of Homeland SecurityInventors: Michael Puckette, Max V. Rasmussen
-
Patent number: 10858633Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.Type: GrantFiled: March 28, 2019Date of Patent: December 8, 2020Assignee: The Government of the United States of America, as represented by the Secretary of Homeland SecurityInventors: Michael Puckette, Max V. Rasmussen
-
Patent number: 10858634Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.Type: GrantFiled: March 28, 2019Date of Patent: December 8, 2020Assignee: The Government of the United States of America, as represented by the Secretary of Homeland SecurityInventors: Michael Puckette, Max V. Rasmussen
-
Patent number: 10829770Abstract: Polynucleotides encoding fusion proteins contain a secretable luciferase fused to a modified polypeptide of interest are disclosed. The polypeptide of interest has been modified to remove a native N-terminal secretion sequence and has been replaced by the secretable luciferase. One example of a modified polypeptide of interest is interferon. The polynucleotides and fusion proteins have biotherapeutic, diagnostic, and quality control applications in biotechnological, medical, and veterinary fields. Methods for producing the secretable fusion protein are also disclosed.Type: GrantFiled: September 16, 2019Date of Patent: November 10, 2020Assignee: The Government of the United States of America, as represented by the Secretary of Homeland SecurityInventors: Michael Puckette, Max V. Rasmussen
-
Publication number: 20200002707Abstract: Polynucleotides encoding fusion proteins contain a secretable luciferase fused to a modified polypeptide of interest are disclosed. The polypeptide of interest has been modified to remove a native N-terminal secretion sequence and has been replaced by the secretable luciferase. One example of a modified polypeptide of interest is interferon. The polynucleotides and fusion proteins have biotherapeutic, diagnostic, and quality control applications in biotechnological, medical, and veterinary fields. Methods for producing the secretable fusion protein are also disclosed.Type: ApplicationFiled: September 16, 2019Publication date: January 2, 2020Applicant: The Government of the United States of America, as represented by the Secretary of Homeland SecurityInventors: Michael Puckette, Max V. Rasmussen
-
Patent number: 10435695Abstract: Polynucleotides encoding fusion proteins comprising interferons and luciferases which have biotherapeutic, diagnostic, and quality control applications in biotechnological, medical, and veterinary fields.Type: GrantFiled: May 1, 2017Date of Patent: October 8, 2019Assignee: The Government of the United States of America, as represented by the Secretary of Homeland SecurityInventors: Michael Puckette, Max V. Rasmussen
-
Patent number: 10385319Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.Type: GrantFiled: September 8, 2016Date of Patent: August 20, 2019Assignee: The Governement of the United States of America, as represented by the Secretary of Homeland SecurityInventors: Michael Puckette, Max V. Rasmussen
-
Publication number: 20190233799Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.Type: ApplicationFiled: March 28, 2019Publication date: August 1, 2019Applicant: The Government of the United States of America, as represented by the Secretary of Homeland SecurityInventors: Michael Puckette, Max V. Rasmussen
-
Publication number: 20190218526Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.Type: ApplicationFiled: March 29, 2019Publication date: July 18, 2019Applicant: The Government of the United States of America, as represented by the Secretary of Homeland SecuritInventors: Michael Puckette, Max V. Rasmussen
-
Publication number: 20190218525Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P 1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.Type: ApplicationFiled: March 28, 2019Publication date: July 18, 2019Applicant: The Government of the United States of America, as represented by the Secretary of Homeland SecurityInventors: Michael Puckette, Max V. Rasmussen
-
Publication number: 20180066235Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.Type: ApplicationFiled: September 8, 2016Publication date: March 8, 2018Applicant: The Government of the United States of America, as represented by the Secretary of Homeland SecurityInventors: Michael Puckette, Max V. Rasmussen
-
Publication number: 20180066267Abstract: Polynucleotides encoding fusion proteins comprising interferons and luciferases which have biotherapeutic, diagnostic, and quality control applications in biotechnological, medical, and veterinary fields.Type: ApplicationFiled: May 1, 2017Publication date: March 8, 2018Applicant: The Government of the United States of America, as represented by the Secretary of Homeland SecurityInventors: Michael Puckette, Max V. Rasmussen